EBS - Emergent cites inquiries from U.S. authorities regarding its COVID-19 vaccine manufacturing

In a regulatory filing yesterday, Emergent BioSolutions (EBS +2.4%) said it had received inquiries and subpoenas from a range of U.S. authorities regarding its ability to conduct COVID-19 vaccine manufacturing. The company’s production plant in Baltimore was subject to an FDA inspection after a manufacturing mix-up made as many as 15M vaccine doses from Johnson & Johnson useless, In April, the federal agency halted operations at the plant. Emergent said it received "preliminary inquiries and subpoenas to produce documents" from the members of the Oversight Committee and the Select Subcommittee on the Coronavirus Crisis, the Department of Justice, the Securities and Exchange Commission (SEC) among others. The Financial Industry Regulatory Authority and New York Attorney General’s Office were also cited as some of the government agencies that had asked for information. The company says it has submitted and in some cases is in the process of handing over the necessary documents

For further details see:

Emergent cites inquiries from U.S. authorities regarding its COVID-19 vaccine manufacturing